Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 20 February 2014 | By Louise Zornoza,
Australia's Therapeutic Goods Administration (TGA) has issued a warning to hip, knee and shoulder implant companies that they will no longer be able to market their products later this year unless they submit reclassification applications for their devices.
Joint implant devices are being reclassified from Class IIb (medium risk devices) to Class III (high risk devices) as of 1 July 2014, and the TGA gave companies a two-year grace period to file reclassification applications in order to ensure that their products could remain on the market.
TGA has reportedly notified each company of the devices that will be targeted for marketing cancellation unless a reclassification application is received by the agency in a timely manner.
Read all Breaking News from RegLink
Regulatory Focus newsletters
All the biggest regulatory news and happenings.